Some aspects of allogeneic stem cell transplantation in patients with myelodysplastic syndrome: advances and controversy

References

• AdèsLItzyksonRFenauxPMyelodysplastic syndromesLancet20143832239225224656536
   PubMed Web of Science ®Google Scholar
• GreenbergPCoxCLeBeauMMInternational scoring system for evaluating prognosis in myelodysplastic syndromesBlood199789207920889058730
   PubMed Web of Science ®Google Scholar
• Garcia-ManeroGMyelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and managementAm J Hematol2014899710824464505
   PubMed Web of Science ®Google Scholar
• PlatzbeckerUMuftiGAllogeneic stem cell transplantation in MDS: how? When?Best Pract Res Clin Haematol20132642142924507818
   PubMed Web of Science ®Google Scholar
• GooleyTAChienJWPergamSAReduced mortality after allogeneic hematopoietic-cell transplantationN Engl J Med20103632091210121105791
   PubMed Web of Science ®Google Scholar
• ScottBLSandmaierBMStorerBMyeloablative vs nonmyeloablative allogeneic transplantation for patients with myelo-dysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysisLeukemia20062012813516270037
   PubMed Web of Science ®Google Scholar
• MartinoRValcárcelDBrunetSSuredaASierraJComparable non-relapse mortality and survival after HLA-identical sibling blood stem cell transplantation with reduced or conventional-intensity preparative regimens for high-risk myelodysplasia or acute myeloid leukemia in first remissionBone Marrow Transplant200841333817982504
   PubMed Web of Science ®Google Scholar
• FenauxPMuftiGJHellstrom-LindbergEEfficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III studyLancet Oncol20091022323219230772
   PubMed Web of Science ®Google Scholar
• OranBKongtimPPopatUCytogenetics, donor type and use of hypomethylating agents in myelodysplastic syndrome with allogeneic stem cell transplantationBiol Blood Marrow Transplant Epub6202014
   Google Scholar
• SierraJPérezWSRozmanCBone marrow transplantation from HLA-identical siblings as treatment for myelodysplasiaBlood20021001997200412200358
   PubMed Web of Science ®Google Scholar
• CutlerCSLeeSJGreenbergPA decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcomeBlood200410457958515039286
   PubMed Web of Science ®Google Scholar
• GiagounidisAHaaseDMorphology, cytogenetics and classification of MDSBest Pract Res Clin Haematol20132633735324507811
   PubMed Web of Science ®Google Scholar
• GreenbergPLTuechlerHSchanzJRevised international prognostic scoring system for myelodysplastic syndromesBlood20121202454246522740453
   PubMed Web of Science ®Google Scholar
• SchanzJTüchlerHSoléFNew comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database mergeJ Clin Oncol20123082082922331955
   PubMed Web of Science ®Google Scholar
• AlessandrinoEPDella PortaMGBacigalupoAWHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO)Blood200811289590218497321
   PubMed Web of Science ®Google Scholar
• BreemsDAVan PuttenWLDe GreefGEMonosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotypeJ Clin Oncol2008264791479718695255
   PubMed Web of Science ®Google Scholar
• van GelderMde WreedeLCScheteligJMonosomal karyotype predicts poor survival after allogeneic stem cell transplantation in chromosome 7 abnormal myelodysplastic syndrome and secondary acute myeloid leukemiaLeukemia20132787988823164802
   PubMed Web of Science ®Google Scholar
• KaoJMMcMillanAGreenbergPLImpact of cytopenias on clinical outcomes in myelodysplastic syndromeAm J Hematol20088376577018645988
   PubMed Web of Science ®Google Scholar
• MalcovatiLDella PortaMGStruppCImpact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS)Haematologica2011961433144021659359
   PubMed Web of Science ®Google Scholar
• CutlerCAllogeneic hematopoietic stem-cell transplantation for myelodysplastic syndromeHematol Am Soc Hematol Educ Program20102010325329
   PubMedGoogle Scholar
• CutlerCPatient selection for transplantation in the myelodysplastic syndromesHematol Oncol Clin North Am20102446947620359638
   PubMed Web of Science ®Google Scholar
• GyurkoczaBDeegHJAllogeneic hematopoietic cell transplantation for MDS: for whom, when and how?Blood Rev20122624725422981712
   PubMed Web of Science ®Google Scholar
• KorethJPidalaJPerezWSRole of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysisJ Clin Oncol2013312662267023797000
   PubMed Web of Science ®Google Scholar
• GreenbergPLAttarEBennettJMNCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromesJ Natl Compr Canc Netw20119305621233243
   PubMed Web of Science ®Google Scholar
• KuendgenAStruppCAivadoMMyelodysplastic syndromes in patients younger than age 50J Clin Oncol2006245358536517088566
   PubMed Web of Science ®Google Scholar
• KuendgenAGattermannNGermingUImproving the prognostic evaluation of patients with lower risk myelodysplastic syndromesLeukemia20092318218418548098
   PubMed Web of Science ®Google Scholar
• OlianskyDMAntinJHBennettJMThe role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based reviewBiol Blood Marrow Transplant20091513717219167676
   PubMed Web of Science ®Google Scholar
• KantarjianHO’BrienSRavandiFProposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring SystemCancer20081131351136118618511
   PubMed Web of Science ®Google Scholar
• MukherjeeSBoccaccioDSekeresMACopelanEAllogeneic hematopoietic cell transplantation for myelodysplastic syndromes – lingering uncertainties and emerging possibilitiesBiol Blood Marrow Transplant Epub7292014
   Google Scholar
• Yakoub-AghaIde La SalmonierePRibaudPAllogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients – report of the French Society of Bone Marrow TransplantationJ Clin Oncol20001896397110694545
   PubMed Web of Science ®Google Scholar
• Castro-MalaspinaHHarrisREGajewskiJUnrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor ProgramBlood2002991943195111877264
   PubMed Web of Science ®Google Scholar
• ArnoldRde WitteTvan BiezenAUnrelated bone marrow transplantation in patients with myelodysplastic syndromes and secondary acute myeloid leukemia: an EBMT survey. European Blood and Marrow Transplantation GroupBone Marrow Transplant199821121312169674854
   PubMed Web of Science ®Google Scholar
• CopelanEAPenzaSLElderPJAnalysis of prognostic factors for allogeneic marrow transplantation following busulfan and cyclophosphamide in myelodysplastic syndrome and after leukemic transformationBone Marrow Transplant2000251219122210871724
   PubMed Web of Science ®Google Scholar
• MartinoRCaballeroMDPérez-SimónJAEvidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromesBlood20021002243224512200391
   PubMed Web of Science ®Google Scholar
• LimZBrandRMartinoRAllogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemiaJ Clin Oncol20102840541120008642
   PubMed Web of Science ®Google Scholar
• MalcovatiLHellström-LindbergEBowenDDiagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNetBlood20131222943296423980065
   PubMed Web of Science ®Google Scholar
• NösslingerTTüchlerHGermingUPrognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromesAnn Oncol20102112012519605511
   PubMed Web of Science ®Google Scholar
• ZippererEPelzDNachtkampKThe hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndromeHaematologica20099472973219336740
   PubMed Web of Science ®Google Scholar
• Della PortaMGMalcovatiLStruppCRisk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndromeHaematologica20119644144921134982
   PubMed Web of Science ®Google Scholar
• SperrWRWimazalFKundiMComorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study GroupAnn Oncol20102111411919605505
   PubMed Web of Science ®Google Scholar
• SorrorMLMarisMBStorbRHematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCTBlood20051062912261915994282
   PubMed Web of Science ®Google Scholar
• ZippererETanhaNStruppCThe myelodysplastic syndrome-comorbidity index provides additional prognostic information on patients stratified according to the revised international prognostic scoring systemHaematologica201499e31e3224463211
   PubMed Web of Science ®Google Scholar
• AppelbaumFRThe role of hematopoietic cell transplantation as therapy for myelodysplasiaBest Pract Res Clin Haematol20112454154722127318
   PubMed Web of Science ®Google Scholar
• ZeidanAMLinharesYGoreSDCurrent therapy of myelodysplastic syndromesBlood Rev20132724325923954262
   PubMed Web of Science ®Google Scholar
• MalcovatiLGermingUKuendgenATime-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromesJ Clin Oncol2007253503351017687155
   PubMed Web of Science ®Google Scholar
• MalcovatiLDella PortaMGPascuttoCPrognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision makingJ Clin Oncol2005237594760316186598
   PubMed Web of Science ®Google Scholar
• Della PortaMGMalcovatiLBoveriEClinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromesJ Clin Oncol20092775476219103730
   PubMed Web of Science ®Google Scholar
• KrögerNZabelinaTvan BiezenAAllogeneic stem cell transplantation for myelodysplastic syndromes with bone marrow fibrosisHaematologica20119629129720971823
   PubMed Web of Science ®Google Scholar
• ArmandPKimHTCutlerCSPrognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantationBlood20071094586458817234738
   PubMed Web of Science ®Google Scholar
• PullarkatVBlanchardSTegtmeierBIron overload adversely affects outcome of allogeneic hematopoietic cell transplantationBone Marrow Transplant20084279980518762767
   PubMed Web of Science ®Google Scholar
• KataokaKNannyaYHangaishiAInfluence of pretransplantation serum ferritin on nonrelapse mortality after myeloablative and nonmyeloablative allogeneic hematopoietic stem cell transplantationBiol Blood Marrow Transplant20091519520419167679
   PubMed Web of Science ®Google Scholar
• MajhailNSBrunsteinCGMcAvoySDoes the hematopoietic cell transplantation specific comorbidity index predict transplant outcomes? A validation study in a large cohort of umbilical cord blood and matched related donor transplantsBiol Blood Marrow Transplant20081498599218721761
   PubMed Web of Science ®Google Scholar
• SivginSBaldaneSKaynarLPretransplant serum ferritin level may be a predictive marker for outcomes in patients having undergone allogeneic hematopoietic stem cell transplantationNeoplasma20125918319022248276
   PubMed Web of Science ®Google Scholar
• BejarRStevensonKAbdel-WahabOClinical effect of point mutations in myelodysplastic syndromesN Engl J Med20113642496250621714648
   PubMed Web of Science ®Google Scholar
• BejarRStevensonKECaugheyBAValidation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromesJ Clin Oncol2012303376338222869879
   PubMed Web of Science ®Google Scholar
• TholFKadeSSchlarmannCFrequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromesBlood20121193578358422389253
   PubMed Web of Science ®Google Scholar
• LinCCHouHAChouWCIDH mutations are closely associated with mutations of DNMT3A, ASXL1 and SRSF2 in patients with myelodysplastic syndromes and are stable during disease evolutionAm J Hematol20148913714424115220
   PubMed Web of Science ®Google Scholar
• SaftLKarimiMGhaderiMp53 Protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q)Haematologica2014991041104924682512
   PubMed Web of Science ®Google Scholar
• WarlickEDO’DonnellPVBorowitzMMyeloablative allogeneic bone marrow transplant using T cell depleted allografts followed by post-transplant GM-CSF in high-risk myelodysplastic syndromesLeukoc Res20083214391447
   Web of Science ®Google Scholar
• WarlickEDCiocADeforTDolanMWeisdorfDAllogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burdenBiol Blood Marrow Transplant2009151303819135940
   PubMed Web of Science ®Google Scholar
• AlyeaEPKimHTHoVImpact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndromeBiol Blood Marrow Transplant2006121047105517067911
   PubMed Web of Science ®Google Scholar
• MartinoRIacobelliSBrandRRetrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromesBlood200610883684616597592
   PubMed Web of Science ®Google Scholar
• TauroSCraddockCPeggsKAllogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasiaJ Clin Oncol2005239387939316314618
   PubMed Web of Science ®Google Scholar
• DeegHJStorerBSlatteryJTConditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndromeBlood20051001201120712149198
   PubMedGoogle Scholar
• GiraltSAHorowitzMWeisdorfDCutlerCReview of stem-cell transplantation for myelodysplastic syndromes in older patients in the context of the Decision Memo for Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome emanating from the Centers for Medicare and Medicaid ServicesJ Clin Oncol20112956657221220586
   PubMed Web of Science ®Google Scholar
• XuFDeegHJCurrent status of allogeneic hematopoietic cell transplantation for MDSCurr Pharm Des2012183215322122571701
   PubMed Web of Science ®Google Scholar
• GiraltSReduced-intensity conditioning regimens for hematologic malignancies: what have we learned over the last 10 years?Hematology Am Soc Hematol Educ Program200538438916304408
   PubMedGoogle Scholar
• AbelGAKorethJOptimal positioning of hematopoietic stem cell transplantation for older patients with myelodysplastic syndromesCurr Opin Hematol20132015015623298879
   PubMed Web of Science ®Google Scholar
• ChangCStorerBEScottBLHematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: Similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disordersBlood20071101379138717488876
   PubMed Web of Science ®Google Scholar
• SlavinSNaglerANaparstekENonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseasesBlood1998917567639446633
   PubMed Web of Science ®Google Scholar
• McSweeneyPANiederwieserDShizuruJAHematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effectsBlood2001973390340011369628
   PubMed Web of Science ®Google Scholar
• MarisMBNiederwieserDSandmaierBMHLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignanciesBlood20031022021203012791654
   PubMed Web of Science ®Google Scholar
• GiraltSBone marrow transplant in myelodysplastic syndromes: new technologies, same questionsCurr Hematol Rep2005420020715865872
   PubMedGoogle Scholar
• ValcárcelDMartinoRCaballeroDSustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survivalJ Clin Oncol20082657758418086801
   PubMed Web of Science ®Google Scholar
• de WitteTHermansJVossenJHaematopoietic stem cell transplantation for patients with myelo-dysplastic syndromes and secondary acute myeloid leukaemias: A report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)Br J Haematol200011062063010997974
   PubMed Web of Science ®Google Scholar
• LimZYHoAYIngramWOutcomes of alemtuzumab-based reduced intensity conditioning stem cell transplantation using unrelated donors for myelodysplastic syndromesBr J Haematol200613520120916939494
   PubMed Web of Science ®Google Scholar
• NakamuraRRodriguezRPalmerJReduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndromeBone Marrow Transplant20074084385017724447
   PubMed Web of Science ®Google Scholar
• FlomenbergNBaxter-LoweLAConferDImpact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcomeBlood20041041923193015191952
   PubMed Web of Science ®Google Scholar
• AversaFTerenziATabilioAFull haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapseJ Clin Oncol2005233447345415753458
   PubMed Web of Science ®Google Scholar
• PeccatoriJForcinaAClericiDSirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donorsLeukemia Epub642014
   Web of Science ®Google Scholar
• BasheyAZhangXSizemoreCAT-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantationJ Clin Oncol2013311310131623423745
   PubMed Web of Science ®Google Scholar
• FenauxPAdèsLHow we treat lower risk myelodysplastic syndromesBlood20131214280428623575446
   PubMed Web of Science ®Google Scholar
• DamajGDuhamelARobinMImpact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des MyélodysplasiesJ Clin Oncol2012304533454023109707
   PubMed Web of Science ®Google Scholar
• GerdsATGooleyTAEsteyEHAppelbaumFRDeegHJScottBLPretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDSBiol Blood Marrow Transplant2012181211121822252125
   PubMed Web of Science ®Google Scholar
• SchroederTCzibereAKrögerNPhase II study of azacitidine (Vidaza®, Aza) and donor lymphocyte infusions (DLI) As first salvage therapy in patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) relapsing after allogeneic hematopoietic stem cell transplantation (allo-SCT): final results from the AZARELA-trial (NCT-00795548)Blood2011118300
   Google Scholar